Team up with VALTOCO® (diazepam nasal spray)
to change the seizure rescue experience at school

Thur, Feb 23 • 3:00 PM - 4:00 PM ET
Presented by:
Vinay Puri, MBBS, MD
Tue, Feb 28 • 12:00 PM - 1:00 PM ET
Presented by:
Vinay Puri, MBBS, MD
Wed, Mar 1 • 1:00 PM - 2:00 PM ET
Thur, Mar 2 • 1:00 PM - 2:00 PM ET


Vinay Puri Headshot
Vinay Puri, MBBS, MD

Professor of Neurology and Pediatrics, Department of Neurology University of Louisville
Director of Child Neurology
Norton Children’s Neuroscience Institute
Louisville, KY

Dr Puri earned his medical degree from Kasturba Medical College in Manipal, India, where he also completed an internship. He completed an internship in pediatrics and a residency in pediatrics at the Henry Ford Hospital in Detroit, Michigan. Dr Puri subsequently completed residencies in neurology at Barnes Hospital in St Louis, Missouri, and in pediatric neurology at St Louis Children’s Hospital. He is Board certified in neurology with a special qualification in child neurology and a subspecialty certification in neurodevelopmental disabilities.

Dr Puri currently serves as the Director and founder at Norton Children’s Neuroscience Institute of Child Neurology, affiliated with the University of Louisville in Kentucky. He is a member of the American Epilepsy Society and Child Neurology Society. Dr Puri has served as a principal investigator or subinvestigator for dozens of clinical trials and has published dozens of articles and abstracts.

Patricia McGoldrick
Patricia McGoldrick, MPA, MSN, CPNP

Clinical Instructor
Columbia University School of Nursing
Department of Pediatrics, New York Medical College
Nurse Practitioner, Epilepsy and Child Neurology
Boston Children's Health Physicians of New York and Connecticut
Hawthorne, NY

Ms McGoldrick earned her Master of Science in Nursing from Columbia University and her Master of Public Administration from New York University in New York City. She has previously held positions as Associate Director of Pediatric Epilepsy Research, Associate Director of the Pediatric Epilepsy Center, Associate Director of the Developmental Disability Center, and Codirector of the Tuberous Sclerosis Clinic and has practiced as a staff nurse in general pediatrics and home care settings. Ms McGoldrick is certified by the Pediatric Nursing Certification Board as a Certified Pediatric Nurse Practitioner.

Ms McGoldrick is currently a nurse practitioner practicing in epilepsy and child neurology at Boston Children’s Health Physicians of New York and Connecticut in Hawthorne, New York. She is also a clinical instructor at the Columbia University School of Nursing and in the Department of Pediatrics at New York Medical College. Ms McGoldrick is a member of the Association of Child Neurology Nurses, American Association of Neuroscience Nurses, and Sigma Theta Tau International and a fellow of the American Epilepsy Society. She has participated in dozens of clinical trials and studies, has delivered dozens of presentations about epilepsy to a variety of audiences, and has published dozens of abstracts, articles, books, and book chapters.

Confidence in the Classroom

Team up with VALTOCO® (diazepam nasal spray) to change the seizure rescue experience at school

VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.



  • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
  • The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction.
  • The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.

Contraindications: VALTOCO is contraindicated in patients with:

  • Hypersensitivity to diazepam
  • Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.


Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Neonatal Sedation and Withdrawal Syndrome

Use of VALTOCO late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Monitor neonates exposed to VALTOCO during pregnancy or labor for signs of sedation and monitor neonates exposed to VALTOCO during pregnancy for signs of withdrawal; manage these neonates accordingly.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including “gasping syndrome,” can occur in neonates and low-birth-weight infants treated with benzyl alcohol–preserved drugs, including VALTOCO. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (

Please read full Prescribing Information, including Boxed Warning, for additional important safety information.

© Neurelis, Inc. 2023. All rights reserved.
NEURELIS, VALTOCO, and the NEURELIS and VALTOCO logos are trademarks or registered trademarks of Neurelis, Inc.
 US-PRC-21-00293 v3 01/2023